(DYN) Dyne Therapeutics - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 3.028m USD | Total Return: 167.6% in 12m

Muscle Disease, Therapeutics, Genetic Disorders
Total Rating 53
Safety 70
Buy Signal -0.31
Biotechnology
Industry Rotation: -3.7
Market Cap: 3.03B
Avg Turnover: 37.5M USD
ATR: 6.03%
Peers RS (IBD): 66.8
Risk 5d forecast
Volatility89.1%
Rel. Tail Risk-17.8%
Reward TTM
Sharpe Ratio1.41
Alpha113.49
Character TTM
Beta1.655
Beta Downside-0.154
Drawdowns 3y
Max DD85.52%
CAGR/Max DD0.32
EPS (Earnings per Share) EPS (Earnings per Share) of DYN over the last years for every Quarter: "2021-03": -0.5, "2021-06": -0.58, "2021-09": -0.83, "2021-12": -1, "2022-03": -0.69, "2022-06": -1.01, "2022-09": -0.8, "2022-12": -0.74, "2023-03": -0.78, "2023-06": -1.08, "2023-09": -0.99, "2023-12": -1.09, "2024-03": -0.81, "2024-06": -0.7, "2024-09": -0.9628, "2024-12": -0.88, "2025-03": -1.05, "2025-06": -0.97, "2025-09": -0.76, "2025-12": -0.73, "2026-03": 0,
EPS CAGR: 68.91%
EPS Trend: 42.4%
Last SUE: 4.00
Qual. Beats: 1
Revenue Revenue of DYN over the last years for every Quarter: 2021-03: 0, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 3.788, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 1.572, 2025-03: 0, 2025-06: 0, 2025-09: 0, 2025-12: 0, 2026-03: null,
Rev. CAGR: 0.00%
Rev. Trend: 8.0%
Last SUE: 0.00
Qual. Beats: 0

Warnings

Share dilution 25.9% YoY - potential capital distress

Interest Coverage Ratio -71.1 is critical

Altman Z'' -7.86 < 1.0 - financial distress zone

Volatile

Tailwinds

No distinct edge detected

Description: DYN Dyne Therapeutics

Dyne Therapeutics, Inc. (DYN) is a clinical-stage biotechnology company. It specializes in developing treatments for neuromuscular diseases.

The company utilizes its proprietary FORCE platform to deliver therapies. This platform targets conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, facioscapulohumeral dystrophy, and Pompe disease. The biotechnology sector is characterized by extensive research and development phases, often requiring significant capital investment before product commercialization.

Dyne Therapeutics was founded in 2017 and is based in Waltham, Massachusetts. Its business model focuses on developing disease-modifying therapeutics for rare diseases, a niche often supported by orphan drug designations and accelerated approval pathways.

For more detailed financial and operational analysis, consider exploring ValueRay.

Headlines to Watch Out For
  • Clinical trial results for myotonic dystrophy type 1
  • Regulatory approval for Duchenne muscular dystrophy treatments
  • FORCE platform technology adoption and licensing deals
  • Competition from other neuromuscular disease therapies
Piotroski VR‑10 (Strict) 0.0
Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM)
FCF/TA: -0.36 > 0.02 and ΔFCF/TA 6.93 > 1.0
NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA -0.34 > 3% & CFO -403.2m > Net Income -446.2m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 22.25 > 1.5 & < 3
Outstanding Shares: last quarter (128.4m) vs 12m ago 25.95% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 0.0% > 50% (prev 0.23%; Δ -0.23% > 0%)
Interest Coverage Ratio: -71.06 > 6 (EBITDA TTM -438.0m / Interest Expense TTM 6.19m)
Altman Z'' -7.86
A: 0.91 (Total Current Assets 1.13b - Total Current Liabilities 50.6m) / Total Assets 1.19b
B: -1.18 (Retained Earnings -1.40b / Total Assets 1.19b)
C: -0.47 (EBIT TTM -440.0m / Avg Total Assets 939.1m)
D: -6.50 (Book Value of Equity -1.40b / Total Liabilities 214.8m)
Altman-Z'' Score: -7.86 = D
What is the price of DYN shares? As of April 11, 2026, the stock is trading at USD 18.68 with a total of 1,218,158 shares traded.
Over the past week, the price has changed by +1.80%, over one month by -5.56%, over three months by +6.99% and over the past year by +167.62%.
Is DYN a buy, sell or hold? Dyne Therapeutics has received a consensus analysts rating of 4.43. Therefore, it is recommended to buy DYN.
  • StrongBuy: 7
  • Buy: 6
  • Hold: 1
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the DYN price?
Analysts Target Price 38.2 104.4%
Dyne Therapeutics (DYN) - Fundamental Data Overview as of 07 April 2026
P/B = 3.1982
P/EG = 0.19
Revenue TTM = 0.0 USD
EBIT TTM = -440.0m USD
EBITDA TTM = -438.0m USD
Long Term Debt = 148.9m USD (from longTermDebt, last quarter)
Short Term Debt = 5.00m USD (from shortTermDebt, last quarter)
Debt = 153.9m USD (corrected: LT Debt 148.9m + ST Debt 5.00m)
Net Debt = -956.6m USD (recalculated: Debt 153.9m - CCE 1.11b)
Enterprise Value = 2.07b USD (3.03b + Debt 153.9m - CCE 1.11b)
Interest Coverage Ratio = -71.06 (Ebit TTM -440.0m / Interest Expense TTM 6.19m)
EV/FCF = -4.89x (Enterprise Value 2.07b / FCF TTM -423.9m)
FCF Yield = -20.46% (FCF TTM -423.9m / Enterprise Value 2.07b)
 FCF Margin = unknown (Revenue TTM is 0 or missing)
 Net Margin = unknown
 Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 1.52m) / Revenue TTM)
 Tobins Q-Ratio = 1.75 (Enterprise Value 2.07b / Total Assets 1.19b)
Interest Expense / Debt = 2.08% (Interest Expense 3.19m / Debt 153.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -347.6m (EBIT -440.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 22.25 (Total Current Assets 1.13b / Total Current Liabilities 50.6m)
Debt / Equity = 0.16 (Debt 153.9m / totalStockholderEquity, last quarter 972.1m)
 Debt / EBITDA = 2.18 (negative EBITDA) (Net Debt -956.6m / EBITDA -438.0m)
 Debt / FCF = 2.26 (negative FCF - burning cash) (Net Debt -956.6m / FCF TTM -423.9m)
 Total Stockholder Equity = 726.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -47.52% (Net Income -446.2m / Total Assets 1.19b)
RoE = -61.45% (Net Income TTM -446.2m / Total Stockholder Equity 726.1m)
RoCE = -50.29% (EBIT -440.0m / Capital Employed (Equity 726.1m + L.T.Debt 148.9m))
 RoIC = -42.77% (negative operating profit) (NOPAT -347.6m / Invested Capital 812.8m)
 WACC = 11.31% (E(3.03b)/V(3.18b) * Re(11.80%) + D(153.9m)/V(3.18b) * Rd(2.08%) * (1-Tc(0.21)))
Discount Rate = 11.80% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 44.64%
 [DCF] Fair Price = unknown (Cash Flow -423.9m)
 EPS Correlation: 42.37 | EPS CAGR: 68.91% | SUE: 4.0 | # QB: 1
Revenue Correlation: 7.98 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.80 | Chg7d=+0.004 | Chg30d=+0.048 | Revisions Net=+4 | Analysts=10
EPS current Year (2026-12-31): EPS=-3.19 | Chg7d=+0.000 | Chg30d=+0.127 | Revisions Net=+7 | Growth EPS=+8.0% | Growth Revenue=+0.0%
EPS next Year (2027-12-31): EPS=-3.03 | Chg7d=+0.019 | Chg30d=-0.101 | Revisions Net=+0 | Growth EPS=+5.0% | Growth Revenue=+0.0%
[Analyst] Revisions Ratio: +0.67 (5 Up / 1 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle